Peter Greenberg, MD, is professor emeritus of hematology at Stanford University. He is also director of the Stanford Myelodysplastic Syndrome (MDS) Center, coordinator of the International Working Group for Prognosis in MDS and chair of the National Comprehensive Cancer Network MDS Practice Guidelines Panel.

Enhance your professional approach to Myelodysplastic Syndromes with our specialized IPSS-R and IPSS-M calculators. Designed for healthcare professionals, these tools provide in-depth prognostic insights to inform strategic decision-making in MDS care.

International Prognostic Scoring System-Revised (IPSS-R) The revised IPSS, known as the “IPSS-R,” covers the same disease factors as the IPSS, but the factors are identified in a more detailed way. The IPSS-R shows five disease factors: The percentage of blasts (immature cells) in the bone marrow

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment. It was developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation.

Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the revised IPSS, but with refinement of the category thresholds and addition of age, performance status, serum ferritin, and LDH.

Revised International Prognostic Scoring System(IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator Advanced Calculator. Developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation, Inc.

2012年9月20日 · Age-adjusted IPSS-R risk categories. The nomogram describes predicted survival based on patient age and IPSS-R risk status (IPSS-RA).

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment. It was developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation.

The International Prognostic Scoring System (IPSS), originally published in 1997, is used by many doctors to help assess the severity of a patient's myelodysplastic syndrome (MDS). Based on the IPSS score, the patient's history, and the physician's own personal observations, the physician will design a treatment plan to address the MDS.

2024年10月10日 · The standard tool for risk stratification in patients with MDS is the Revised International Prognostic Scoring System (IPSS-R). IPSS-R is an updated version of the previous IPSS, which was revised to include additional factors to predict outcomes more accurately. What are the IPSS-R Risk Categories?